Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment

被引：1
|
作者：
Peng, Yongquan [1 ]
Cao, Xujian [1 ]
Wang, Yating [1 ]
Yu, Weiwei [2 ]
Zeng, Ziwei [2 ]
Wang, Min [2 ]
机构：
[1] Univ South China, Hosp Changsha 1, Grad Collaborat Training Base, Grad Collaborat Training Base, Hengyang 421001, Hunan, Peoples R China
[2] First Hosp Changsha, Inst HIV AIDS, Changsha 410000, Hunan, Peoples R China
来源：
CHINESE MEDICAL JOURNAL | 2023年 / 136卷 / 22期
关键词：
D O I：
10.1097/CM9.0000000000002888
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2738 / 2740
页数：3
相关论文
共 50 条
  • [21] Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts
    Esser, Stefan
    Brunetta, Jason
    Inciarte, Alexy
    Levy, Itzchak
    D'Arminio Monforte, Antonella
    Lambert, John S.
    van Welzen, Berend
    Teruya, Katsuji
    Boffito, Marta
    Liu, Chun-Eng
    Altuntas Aydin, Ozlem
    Thorpe, David
    Heinzkill, Marion
    Marongiu, Andrea
    Cassidy, Tali
    Haubrich, Richard
    D'Amato, Lisa
    Robineau, Olivier
    HIV MEDICINE, 2024, 25 (04) : 440 - 453
  • [22] Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate for adult patients with human immunodeficiency virus-1 in China: a retrospective real-world cohort study
    Gan, Lin
    Xie, Xiaoxin
    Fu, Yanhua
    Song, Yebing
    Song, Chunli
    Ren, Tingting
    Long, Hai
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024, 22 (04) : 211 - 217
  • [23] Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically suppressed: real-world data from the ICONA cohort
    Monforte, A. d'Arminio
    Tavelli, A.
    Cingolani, A.
    Taramasso, L.
    Mussini, C.
    Piconi, S.
    Calcagno, A.
    Orofino, G.
    Cicalini, S.
    Castagna, A.
    Ceccherini-Silberstein, F.
    Gori, A.
    Guaraldi, G.
    Antinori, A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 98 - 99
  • [24] Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BTC/FTC/TAF) in ART-naive patients: real-world data from the ICONA cohort
    Tavelli, A.
    Marchetti, G.
    Vergori, A.
    Quiros-Roldan, E.
    Malagnino, V.
    Vichi, F.
    Lichtner, M.
    Nozza, S.
    Rossotti, R.
    Sarmati, L.
    Bai, F.
    Di Biagio, A.
    Antinori, A.
    Monforte, A. d'Arminio
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 62 - 63
  • [25] Eficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in patients with pre-existing NRTI resistances: real world data
    Mican, R.
    Grela, A. de Gea
    Busca, C.
    Bernardino, J. I.
    Montejano, R.
    Montes, M.
    Cardinanos, J.
    de Miguel, R.
    Serrano, L.
    Perez-Valero, I.
    Valencia, E.
    Moreno, V.
    Arribas, J. R.
    Gonzalez-Garcia, J.
    Martin-Carbonero, L.
    HIV MEDICINE, 2021, 22 : 30 - 31
  • [26] Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy
    Andreatta, Kristen
    Sax, Paul E.
    Wohl, David
    D'Antoni, Michelle L.
    Liu, Hui
    Hindman, Jason T.
    Callebaut, Christian
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024,
  • [27] The clinical relevance of potential drug-drug interactions with bictegravir/emtricitabine/tenofovir alafenamide - Real-world data from the German IQVIA prescription database
    Umland, T.
    Stellbrink, H.
    Calvo, M.
    Zahn, A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 88 - 90
  • [28] Patient-reported outcomes among people living with HIV on bictegravir/ emtricitabine/tenofovir alafenamide fixed-dose combination: Real-world data from Latin America
    Cecchini, D. M.
    Seleme, S.
    Mingrone, M. V.
    Diana Menendez, S.
    Mauas, R.
    Bottaro, E.
    Cassetti, I.
    HIV MEDICINE, 2023, 24 : 414 - 414
  • [29] A retrospective, multicentre study on the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for the treatment of HIV in a real-world setting in Belgium
    Nasreddine, R.
    Florence, E.
    Yombi, J.
    Henrard, S.
    Darcis, G.
    Van Praet, J.
    Vandekerckhove, L.
    Allard, S.
    Demeester, R.
    Messiaen, P.
    Ausselet, N.
    Delforge, M.
    De Wit, S.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 116 - 117
  • [30] Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China
    Cao Jing
    Tang Wei
    Wang Ning
    Zheng Fang
    Xiao Gang
    Wang Xingzhi
    Zhou Guoqiang
    Wang Min
    BMC Infectious Diseases, 23
12345